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Abstract
Infection with human papillomavirus (HPV), the sexually transmitted virus that causes cervical
and other types of cancer, can be prevented. A safe and effective vaccine has been approved for
both boys and girls. Despite this recommendation and alarming rates of HPV-associated cancers,
vaccination rates among adolescents in the United States are low. A capstone project was
implemented to target students and parents of students who attend Holyoke High School and
William J. Dean Vocational Technical High (Dean Tech) in Holyoke, Massachusetts. The goals
of the project were to improve knowledge about HPV and the HPV vaccine in students and
parents, to increase the number of parents of adolescents who intend to vaccinate their children
against HPV, and to increase the number of adolescents who intend to receive the HPV vaccine.
The project was based on the theoretical framework of the Health Belief Model. Students in
ninth grade health classes at both schools were taught content about HPV and why they should
receive the HPV vaccine. An informational handout was sent home with all ninth grade students
at the schools and reminded them that the school-based health center (SBHC) had the HPV
vaccine available. Outreach to parents was done at two community events. The research
translation method that was used for this project is an educational intervention that utilized the
Plan-Do-Study-Act (PDSA) model. Evaluation of this project was done with a pre-test post-test
design with the ninth grade students. The results showed an increase in knowledge and increase
in intent among the students to get vaccinated against HPV. No formal data was gathered from
the parents. Knowledge gained from this capstone project should encourage nurses to continue
educating adolescents and their parents about the HPV vaccine and showed that SBHCs are a
promising site to increase HPV vaccination rates.
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Increasing Knowledge About HPV and the HPV Vaccine Amongst Adolescents and Adults
Through a School-Based Setting: A Capstone Project
In June of 2006, the United States (U.S) Food and Drug Administration (FDA) released a
statement that the vaccine Gardasil® had been approved for use to prevent four types of human
papillomavirus (HPV) that can cause cervical, vaginal, and vulvar cancer and genital warts in
women (U.S. FDA, 2006). This was groundbreaking medical news. Headlines around the world
announced the news of the first ever vaccine to prevent cancer (British Broadcast Company,
2006; Harris, 2006; Rubin, 2006). Another vaccine, Cervarix®, was released in 2009. Cervarix®
prevents two types of HPV that can cause cervical cancer and precancerous lesions (U.S. FDA,
2009).
There are many types of cancer that are related to HPV. According to the Centers for
Disease Control and Prevention (CDC) (2011a), almost all cases of cervical cancer are caused by
HPV. Ninety percent of anal cancers, 65% of vaginal cancers (De Vuyst, Clifford, Nascimento,
Madeleine, & Franceschi, 2008), 50% of vulvar cancers, 35% of penile cancers (Parkin & Bray,
2006), and 60% of oropharyngeal cancers (Kreimer, Clifford, Boyle, & Franceschi, 2005) can be
attributed to HPV infection. The CDC (2012b) estimates that over 20 million Americans are
infected with HPV and every year there are 6 million new cases of HPV infection.
There are over 40 types of HPV virus. Types 16 and 18 are the most oncogenic strains of
the HPV virus. They are responsible for causing over 70% of cases of cervical cancer and a large
proportion of other types of genital cancer. HPV types 6 and 11 are responsible for causing over
90% of cases of genital warts. Cervarix® is a bivalent vaccine that prevents HPV types 16 and
18. Gardasil® is a quadrivalent vaccine that prevents HPV types 6, 11, 16, and 18 (CDC, 2012b).
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The Advisory Committee for Immunization Practices (ACIP) is a group of medical and
public health experts that are appointed by the Secretary of the U.S. Department of Health and
Human Services to make recommendations about vaccines for residents of the U.S. (CDC,
2012a). ACIP first recommended in 2006 that females between the ages of 9-26 be vaccinated
with Gardasil® to prevent cervical cancer and genital warts (CDC, 2007). In October 2009,
ACIP recommended that all males between the ages of 9-26 be vaccinated with Gardasil® to
prevent genital warts (CDC, 2010). In December 2011, ACIP again recommended all males and
females between the ages of 9-26 be vaccinated with Gardasil® because the vaccine can also
prevent anal cancer (CDC, 2011b). In 2011, ACIP also recommended that routine HPV
vaccination begin in males and females starting at age 11, but the vaccine can still be given as
early as age nine if parents are willing and provide consent. This age is recommended because
ideally the vaccine should be given before the adolescent has sexual contact for the first time
(CDC, 2011b). A study published in 2004 by Weinstock, Berman, and Cates Jr. revealed that
even though youth, ages 15-24, only account for about a quarter of the sexually active population,
they account for over half of all new sexually transmitted diseases (STDs) in the U.S. each year.
The CDC (2012b) predicted that at least 50% of individuals will have been exposed to
the HPV virus at some point during their lifetime. Approximately 90% of people’s immune
systems will clear the virus from their body within two years, but for the 10% who are unable to
clear it, HPV can cause genital warts or types of cancer. This is why vaccination for males and
females against HPV is important.
Problem
In 2012, it was estimated that 12,170 women would be diagnosed with invasive cervical
cancer and that 4,220 women would die from the disease in the U.S. (American Cancer Society,
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2012). Cervical cancer rates have significantly improved over time since the advent of the
Papanicolaou (Pap) test, but women are still dying from a disease that doctors can effectively
screen for and now have a preventative vaccine (National Cancer Institute, 2012b). Women of
color and of lower socioeconomic status are disproportionately affected by cervical cancer. The
CDC (2012d) reported that Black and Hispanic women have higher rates of cervical cancer than
white women. From 2004-2008, 9.9/100,000 Black women and 11.3/100,000 Hispanic women
were diagnosed with cervical cancer compared with 7.4/100,000 white women. It is unclear
whether the rates are higher due to incidence of disease or because Black and Hispanic women
have less access to screening and treatment than white women. The National Cancer Institute
(2012a) reported from 1998 to 2010, women who lived in households with incomes at less than
200 percent of the poverty level or had not graduated from high school, were less like to have
had a Pap test.
The CDC (2012h) estimated there are about 3,100 new cases of HPV-associated vulvar
cancer every year in the U.S. From 2004-2008, there were 1.9/100,000 cases in white women
compared with 1.4/100,000 cases in Black women and 1.2/100,000 cases in Hispanic women.
There were very few cases of HPV-associated vaginal cancer. The CDC (2012g) estimated there
are about 740 new cases per year. Black women had the highest rates from 2004-2008 at 0.7
cases per 100,000 women while white and Hispanic women had 0.4 cases per 100,000 women.
HPV-associated penile cancer is also another rare cancer in the U.S. The CDC (2012f)
estimated there are about 1,000 new cases per year. From 2004-2008, Hispanic men had the
highest rates at 1.3/100,000 men, compared with 0.7/100,000 in non-Hispanic men. The CDC
(2012c) estimated there are about 3,000 new cases of HPV-associated anal cancer each year.
White women and Black men have more cases of anal cancer than women and men of other
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races. Men are disproportionately affected by HPV-associated oropharyngeal cancer. The CDC
(2012e) estimated there are 9,356 new cases in men and 2,370 new cases in women every year.
White and Black men and women have higher rates of oropharyngeal cancer than Hispanic men
and women.
Despite these staggering cancer statistics, the groundbreaking news about the HPV
vaccine, startling HPV statistics, and the ACIP recommendations, rates of HPV vaccination
remain the lowest of all adolescent vaccines in the U.S. (Hughes, Jones, Feemster, & Fiks, 2011).
A report recently released by the CDC (2012j) discussed vaccination rates of males and females,
ages 13-17. As of 2011, only 34.8% of females and 1.3% of males had received all three doses of
the HPV vaccine. The rate of females who had received at least one dose of the HPV vaccine
increased from 48.7% in 2010 to 53% in 2011. Females, ages 14-17, were significantly more
likely to have received a dose of the vaccine than females under the age of 13.
HPV vaccine initiation, in both males and females ages 13-17, was higher for Blacks and
Hispanics than whites and vaccine completion was higher in Hispanics. Completion of the HPV
vaccine series was lower in Black females than white females. In both sexes, vaccination rates
were higher for adolescents living below the poverty line than those living at or above the
poverty line except that females living below the poverty line had lower vaccine completion rates
(CDC, 2012i).
HPV vaccination rates significantly vary by state. As of 2011, in youth ages 13-17,
31.9% of females in Mississippi had received at least one dose of the HPV vaccine, compared
with 76.1% in Rhode Island. Females who had received all three doses of the vaccine were
lowest in Arkansas at 15.5% as opposed to the highest rates in Rhode Island at 56.8%. In
Massachusetts (Mass.), 61.1% of females had received at least one dose and 48.5% had received
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three doses of the HPV vaccine. The rate of males who had received at least one dose in the state
was 5.8% (CDC, 2012j). One of the goals of Healthy People 2020 is for 80% of girls between
the ages of 13-15 in the U.S. to have received all three doses of the HPV vaccine (U.S. Dept. of
HHS, 2012). Currently the U.S. is not on track to reach this goal.
Review of Literature
Review of the Evidence
An extensive search of the literature was performed to answer the question: how can
nurses increase knowledge about HPV and the HPV vaccine and increase vaccination rates in
adolescents? The search was performed in PubMed of the National Library of Medicine and the
Current Index to Nursing Allied Health Literature (CINAHL). The search terms that were used
included: “adolescents,” “HPV vaccine,” “HPV,” and “school-based vaccination programs.” The
following limits were placed in the search: English language, items with abstracts, and free full
text articles. No time frame was specified due to the fact that HPV vaccination only began in
2006. Inclusion criteria included articles related to increasing HPV vaccination rates in
adolescents, parental opinions on why they are or are not consenting to vaccinating their children
against HPV, and administration of vaccines in a school-based setting. Exclusion criteria
included articles that did not pertain to adolescents.
The search in PubMed yielded 485 results. Fifty-four abstracts were assessed and ten
were kept for inclusion in this review. The search in CINAHL yielded 83 results. Seventeen
abstracts were assessed and three were kept for inclusion in this review. The rest of the articles
used in this literature review were obtained from reviewing the bibliographies of already
obtained studies
The literature review revealed a few overarching themes. Firstly, there are many reasons
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parents (any time parents are referenced in this proposal, the author is referencing the legal
guardian of the child) decide not to vaccinate their children against HPV, including: lack of
education, questions about the safety of the vaccine, and that they do not think their children are
sexually active. The review also revealed that schools are a promising venue to educate
adolescents and their parents/legal guardians about HPV and the HPV vaccine and increase HPV
vaccination rates.
Reasons why adolescents have not received the HPV vaccine. There are many reasons
why parents are reluctant to have their adolescent children vaccinated against HPV such as fear
of side effects, but active refusal is not always the reason, often times it is lack of education.
Many parents are not well informed about HPV and the vaccine, especially related to vaccinating
boys.
Lack of education. Many parents and adolescents were not aware of HPV and the HPV
vaccine or do not have enough information to make an educated decision about the HPV vaccine
(Hughes et al., 2011; Read, Joseph, Polishchuk, & Suss, 2010; Sotiriadis, Dagklis, Siamanta,
Chatzigeorgiou, & Agorastos, 2012). Bair, Mays, Sturm, and Zimet (2008) conducted a
qualitative study where they interviewed 40 Latina mothers from an urban pediatric clinic. The
mothers had daughters that were between the ages of 7-14. Seventy-eight percent of the mothers
had not heard of HPV and 68% of the sample knew nothing about cervical cancer. All mothers in
the sample reported having had a Pap smear, but 85% of them did not know about the connection
between HPV and Pap smears. After receiving information about the HPV vaccine, 80% of the
mothers stated they would allow their daughters to receive the HPV vaccine. The eight mothers
who did not agree stated they needed more information about the HPV vaccine and/or their
daughter was too young.
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A qualitative study conducted in New South Wales, Australia by Bernard, Cooper
Robbins, McCaffery, Scott, and Skinner (2011) looked at fear, the fear response, and factors
affecting fear in adolescent girls who were going to receive the HPV vaccine. Girls from nine
schools between the ages of 12-16 were either observed on the vaccination days at school or
were interviewed in focus groups. Three fear responses were recorded: fear of pain, fear of
having needle pierce skin, and fear of vaccine content and possible side effects. The results
showed that the girls fear responses exacerbated the responses of their peers, girls were more
stressed when waiting in large groups with peers, and the lack of privacy made fear worse. The
results also reported that most girls knew very little about HPV and why they were receiving the
vaccine. The misinformation that many of the girls received about the vaccine came through
rumors from friends and family. The three-dose HPV vaccination rate ranged from 64%-90%
among girls from those schools.
Cates, Ortiz, Shafer, Smith Romocki, and Coyne-Beasley (2012) performed a two phase
qualitative study with Black parents/caregivers of 11 and 12 year old boys in North Carolina
about designing messages to motivate parents/caregivers to vaccinate their sons against HPV.
During the first phase of the study focus groups were conducted with parents/caregivers.
Participants were recruited from churches and a middle school. Twenty-nine parents/caregivers
made up the focus group sample and 76% of them were female. Results showed
parents/caregivers were uninformed about HPV. Almost all parents were unaware that HPV can
have serious effects on boys. Many thought HPV was only problematic for girls and they were
surprised to hear that the HPV vaccine is recommended for boys. During the second phase of the
study, intercept interviews were done with 100 parents/caregivers at a pediatric and adolescent
clinic. Seventy-seven percent of the sample was female caregivers. This study did not
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specifically target females, but female parents/caregivers are the ones who more often chose to
participate or were the ones bringing the child to an appointment. Results from the intercept
interviews showed that only 11% of parents had heard of the HPV vaccine being recommended
for boys.
Vaccine safety. Vaccine safety and efficacy is one of the most common reasons for HPV
vaccine refusal cited by parents of adolescents (Gilkey, Moss, McRee, & Brewer, 2012).
Dempsey, Abraham, Dalton, and Ruffin (2009) performed a qualitative study of 52 mothers of
11-17 year old girls in Michigan. The mothers completed a telephone survey and answered
questions about reasons why they accepted or declined the HPV vaccine for their daughters.
Thirty-three mothers had accepted the HPV vaccine and 19 had declined vaccine for their
daughters. Those who declined the vaccine had significant concerns about the safety of the HPV
vaccine. They also generally felt their daughters were at low risk for HPV or were too young to
receive the vaccine.
Fear of side effects from the vaccine is another commonly cited reason by parents who
have not vaccinated their children against HPV (Bernard, Cooper Robbins, McCaffery, Scott, &
Skinner, 2011; Kester, Zimet, Fortenberry, Kahn, & Shew, 2012). Sotiriadis, Dagklis, Siamanta,
Chatzigeorgiou, and Agorastos (2012) performed a qualitative study in Greece of 5,249 women
who had a 13-year-old son or daughter. The mothers filled out a survey to explore the factors
affecting women’s acceptability of the vaccine for themselves, their daughters and their sons.
The acceptability rate for vaccination of their daughters was 78.3% and 77.5% for their sons. The
most common reasons cited by mothers about refusal of the vaccine were fear of adverse events
and lack of knowledge about HPV and vaccination. The intention to vaccinate their children
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decreased significantly after the vaccine became available in Greece and it coincided with a rise
in mothers who were concerned about its potential side effects.
Lu, Kimar, Castellsague, and Giuliano (2011) conducted a systematic review and metaanalysis on the safety and efficacy of HPV vaccines. The study included 13 publications
representing seven randomized control trials. Results showed vaccines are highly efficacious in
preventing HPV infection and associated precancerous lesions. Local and systemic side effects
were generally mild. The most serious side effect was abnormal pregnancy related outcomes and
this was rare.
A case study published by Watson, Shaw, Mochanoff, and McInnes (2009) described the
implementation of an HPV school vaccination program in South Australia. Side effects reported
by the adolescent girls were similar to those reported in the meta-analysis by Lu et al. (2011).
The most common side effects reported were nausea, headache, injection site reaction, fever and
rash. There was report of numbness in limbs, seizure, neck stiffness and a urinary tract infection
but it is unclear whether these symptoms can be directly associated with the HPV vaccine. The
program was offered to 50,191 female students in school classes 8-12 across 219 schools. HPV
vaccination initiation was highest in year 8 at 83% and year 10 at 70%. Vaccination rates of
doses two and three varied from 55% to 77% amongst the classes. The rates were impressive
given that the vaccine initiative was announced after the school year had begun and coordination
and implementation was completed within a six-month period.
Parents do not think children are sexually active. According to the CDC (2011b), the
ideal time for adolescents to receive the HPV vaccine is between the ages of 9 to 12 so that it is
provided before their first sexual encounter Many parents delay getting their adolescents
vaccinated because they do not think their children are sexually active when they are (Bair et al.,
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2008; Dempsey et al., 2009; Dorrell, Yankey, & Strasser, 2009; Hughes et al., 2011).
A qualitative study conducted by Read, Joseph, Polishchuk, and Suss (2010)
administered a survey to girls and their parents at an urban health clinic to assess knowledge and
attitudes about HPV and the vaccine. The sample was made up of girls who predominantly are of
African-American or Caribbean descent. Results revealed early sexual initiation by the girls. Out
of the sample of 175 girls ages 13-19, 48.9% reported being sexually active at an average age of
14.9 years. Over half of the girls who reported being sexually active have had more than one
lifetime sexual partner. Only 55.8% of girls knew what HPV was. Seventy-two parents
participated in the survey and 38.9% of them reported they were unsure about the HPV vaccine
and 23.6% of parents stated they would refuse the vaccine for their daughter. The most common
reason for refusal reported by parents was not having enough information about HPV and the
vaccine.
Schools and the HPV vaccine. School-based health centers (SBHCs) and school-based
vaccination programs are quite common in other parts of the world and HPV vaccination
programs have been successful in these settings. SBHCs and school-based vaccination programs
are not as common in the U.S., but they are slowly increasing in number and the majority of
parents support them. Gustafson (2005) wrote an article about the history of SBHCs in the U.S.
In 1990, there were only 200 SBHCs located in 45 states plus the District of Columbia, but that
number increased to over 1500 by 2002. Sixty-one percent of SBHCs are in urban areas, 27% in
rural areas, and 12% in suburban areas. SBHCs are mostly nurse managed with nurse
practitioners and other healthcare providers. The mission of SBHCs is to provide access to
primary care and preventative care for kids who are the least likely to access regular care within
their communities.
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In England, a national school-based vaccination program with Cervarix® began during
the 2008/2009 school year. Statistics show that in its first year, 80.1% of 12-13 year old girls
received the three-dose series. In the 2009/2010 school year, 76.4% of girls ages 12-13 had
received all three doses of the vaccine, 82.3% had received at least two doses, and 84.3% had
received at least one dose of the HPV vaccine (Sheridan & White, 2010). Vaccination rates in
other countries are well above the rates among females of the same age in the U.S.
The literature search also highlighted studies with results that show parents are supportive
of school-based vaccination programs. Reiter, Stubbs, Panozzo, Whitesell, and Brewer (2011)
identified that parents, healthcare providers and school staff members are the key stakeholders in
regards to adolescent females and HPV vaccination. An HPV education campaign was
conducted throughout Guilford County, North Carolina. Numerous 30-40 minute informational
sessions were held for groups made up of the key stakeholders. Data was reported from 118
healthcare staff members, 456 school staff members, and 376 parents who attended the
intervention sessions and 91% of them were female. Healthcare and school staff completed preand post-session surveys during the intervention. Surveys assessed objective knowledge about
HPV and asked opinion-based questions regarding the HPV vaccine and schools. Before the
intervention, 86% of school staff members felt middle schools were appropriate venues for HPV
education and vaccination programs, but after the intervention, the number increased to 91%.
Before the intervention, 79% of school staff members stated they were supportive of schoolbased vaccination clinics and after the interventions, 85% stated they were supportive. Parents
did not fill out surveys before the intervention, but after the intervention, 97% of them stated
they would be supportive of a school-based vaccination clinic.
A large qualitative study conducted by Middleman and Tung (2011) assessed the
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association between parents’ perspectives on school-located immunization programs and the
subsequent implementation of a school-located immunization programs. A sample of 1,377
parents who had children in middle school completed a pre-program questionnaire and 777
parents returned a consent or refusal form for their child to be vaccinated at school. An
unexpected finding appeared in the results of this study. Forty-two percent of parents who
consented to having their child vaccinated at school had indicated in their pre-program survey
that schools were not a preferred place for children to receive vaccines. The authors suggested
that rates of parents who actually consent for their child to receive vaccines at school might be
higher than expected from responses on assessing parental attitudes about school-based
vaccination. This study was not about HPV vaccine, only tetanus, diphtheria, acellular pertussis
(Tdap) and meningococcal vaccines were being offered to the adolescents.
A qualitative cross-sectional study conducted by Kelminson et al. (2012) mailed surveys
home to 805 parents of incoming sixth grade students in three public middle schools in Aurora,
Colorado. The purpose of the survey was to assess parental attitudes about administering
vaccines at school. Five hundred surveys were returned and 85% of those who completed the
survey were female. This study did not target mothers, but they were the ones choosing to fill out
the surveys about their child’s health. Seventy-one percent of parents stated they would consent
to their children receiving vaccines at school. More parents stated they would consent for their
children to receive the Tdap or meningococcal vaccine than the HPV vaccine, but 72% of parents
responded that they would consent for their children to receive the HPV vaccine at school.
Reiter, McRee, Pepper, and Brewer (2012) conducted a qualitative study that sent an
online survey to parents in the U.S. with adolescent sons aged 11-17. The study assessed
attitudes and beliefs about HPV vaccination and boys. Four hundred and four parents completed
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the survey and 54% were female and 46% were male. This is the only study from the literature
search that had a sample of nearly equal participation of both mothers and fathers The authors
did not report any reason as to how or why so many fathers completed the survey. Parents were
presented with mock situations that offered to vaccinate their children at a school clinic. As other
studies have shown, parents agreed to the HPV vaccination more often when the HPV vaccine
was offered with other routine vaccinations required for adolescents. Parents also agreed to the
HPV vaccination more often when presented with a consent form for them to “opt-in” rather than
“opt-out” of the vaccination for their children.
Kadis et al. (2011) performed a study about whether mothers would support an HPV
vaccination program in their child’s school. The nationally representative sample consisted of
496 mothers of 11-14 year-old females who completed an online survey. Out of the sample, 20%
of mothers reported that their daughters had already completed the series of HPV vaccination,
31% of mothers reported that their daughters had received at least one dose of the vaccine, and
48% stated they intended to have their daughter vaccinated within the next year. Sixty-seven
percent of the mothers who had already had their daughters receive one or all of the HPV
vaccines or intended to vaccinate their daughters against HPV stated they would agree to their
daughters receiving the HPV vaccine at school.
Synthesis of the Evidence
The majority of the studies had a qualitative design, which is considered a lower level of
evidence according to the Johns Hopkins Nursing Evidence-Based Practice Rating Scale
(Newhouse, Dearholt, Poe, Pugh, & White, 2007), but qualitative studies are appropriate for
answering the question: how can nurses increase awareness about HPV and the HPV vaccine and
increase vaccination rates in adolescents? One limitation of many of the articles was the use of
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convenience samples. Another limitation of many of the articles was that the results were not
generalizable to the U.S. populations because either the study was performed in another country
or only in a small area of the U.S. Despite these limitations, the literature review provides many
avenues that nurses can follow to increase awareness about HPV and the HPV vaccine and
increase vaccination rates in adolescents
Nursing interventions need to primarily focus on increasing general educational messages
about HPV and the vaccine for both parents and adolescents. The literature clearly reveals that
lack of education is one of the biggest, if not the biggest reason why HPV vaccination rates are
so low. Outreach to parents of adolescents, particularly parents of boys, is imperative to educate
them that their adolescents should receive the HPV vaccine, as many parents are still unaware
that the HPV vaccine is recommended for boys as well as girls. Educational messages should
also include information that the HPV vaccine is safe, but inform parents and adolescents about
the most common side effects associated with the vaccine.
Schools that have SBHCs and/or school-based vaccination programs are promising
avenues to increase knowledge about HPV and the HPV vaccine and increase HPV vaccination
rates. HPV vaccination programs at SBHCs in other parts of the world have been highly
successfully and have had vaccination rates of up to 90% (Bernard et al, 2011). As the literature
review revealed, a large number of parents stated they would consent to their child receiving
vaccinations at school and the results from one study showed that when the vaccination program
was actually implemented, more parents consented to their child receiving vaccines than was
anticipated from results of pre-program survey. Nurses can educate parents and adolescents
about HPV and the HPV vaccine at schools that have SBHCs and remind them that the
adolescent can receive the HPV vaccine at school. Having adolescents vaccinated at school also
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provides an opportunity to decrease the rates of missed opportunities. Healthcare providers
working at the SBHCs can ensure that adolescents already coming in for routine physicals and/or
other recommended vaccines also get the HPV vaccine.
The literature review identified barriers to vaccinating adolescents against HPV. One
barrier is the fear response adolescent girls have toward vaccinations/injections. They have fears
of pain and having the needle pierce their skin. Concern about safety of the HPV vaccine and its
possible side effects are also major barriers. Both parents and adolescents have identified with
this concern. Another barrier are parents who think the HPV vaccine is not yet necessary for
their children because they do not think their children are sexually active, when in fact they are..
Theoretical Framework
It is essential to have a theoretical framework on which to focus implementation of
research-based interventions in practice (White & Dudley-Brown, 2012). One such theory is the
Health Belief Model (HBM). This model (Appendix A) is composed of six constructs that
“…influence people’s decisions about whether to take action to prevent, screen for and control
illness” (NCI, 2005, p. 13). The HBM can be applied to an evidence-based intervention to
increase knowledge in parents and adolescents about HPV and the HPV vaccine and increase
HPV vaccination rates in adolescents.
The authors of the HBM state people will be ready to act on a health decision if all six of
the constructs are present. The first construct is perceived susceptibility. People must believe
they are susceptible to the condition. The second construct is perceived severity. People must
believe the condition has serious consequences. The third construct is perceived benefits. People
must believe taking action would reduce their susceptibility or its severity. The fourth construct
is perceived barriers. People must believe the costs of taking the action are outweighed by the
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benefits. The fifth construct is cue to action. People must be exposed to factors that prompt
action. The sixth and final construct is self-efficacy. People must feel confident in their ability to
successfully perform the action. The authors comment that health motivation is central to the
HBM and the model is useful for designing short and long-term behavior change strategies (NCI,
2005).
The HBM can be applied to a scenario where a mother and her son decide whether to
vaccinate the son against HPV. The adolescent son receives education about HPV and the HPV
vaccine in his health class at school and his mother hears similar information at a meeting she
attended in the community (perceived susceptibility). Both mother and son learn that HPV can
cause genital warts and cancer in males and females (perceived severity). They both learn that
the HPV vaccine is recommended for adolescents, ages 9-26, and can prevent the son from
getting the most common types of HPV that cause genital warts and cancer (perceived benefits).
The mother and son learn that the HPV vaccine is safe and are aware of the most common side
effects caused by the vaccine. They learn that the HPV vaccine is covered by most insurance
companies and is available at the SBHC at the son’s school and/or at his primary care provider’s
office (perceived barriers). After hearing this information, the mother and son are both provided
information to take home with the contact information of the SBHC and how to make an
appointment for the son to receive the vaccine. The mother and son decide that the son should
receive the HPV vaccination and call to make an appointment (cue to action and self-efficacy).
Project Description, Implementation, and Monitoring
Population/Community
The city of Holyoke is in the western part of the Commonwealth of Massachusetts. It is
located in Hampden County. The population of Holyoke in 2010 was 39,880 people. Out of the

INCREASING HPV VACCINATION RATES

21

39,880 people living in Holyoke 19,313 (48.4%) people identified themselves as Hispanic or
Latino and 20,567 (51.6%) identified themselves as not Hispanic or Latino. Of those who did not
identify as Hispanic or Latino, 18,651 (46.8%) identified as white alone, 961 (2.4%) as Black or
African American alone, 402 (1%) as Asian alone, 7 (0%) as Native Hawaiian or Pacific Islander
alone, 43 (0.1%) as American Indian or Alaska Native alone, 61 (0.2%) as some other race alone,
and 442 (1.1%) identified as two or more races. (U.S. Census Bureau, 2010).
Holyoke has two public high schools, Holyoke High School and William J. Dean
Vocational Technical High (Dean Tech) with students in grades 9-12. During the 2012/2013
school year, 1,354 students were enrolled at Holyoke High School (Massachusetts (Mass.)
Department (Dept.) of Elementary and Secondary Education (ESE), 2013a) and 517 at Dean
Tech (Mass Dept. of ESE, 2013c). Out of the 1,354 students at Holyoke High School, 3.3%
identified as African American, 0.9% Asian, 68.9% Hispanic, 0% Native American, 26.4% white,
0% Native Hawaiian or Pacific Islander, and 0.5% identified as multi-race, non-Hispanic (Mass
Dept. of ESE, 2013a). Out of the 517 students at Dean Tech, 1.5% identified as African
American, 0.2% Asian, 91.3% Hispanic, 0% Native American, 6.8% white, 0.2% Native
Hawaiian or Pacific Islander, and 0% identified as multi-race, non-Hispanic (Mass Dept. of ESE,
2013c). Among the student body at Holyoke High School, 46.3% of students’ first language is
not English and 10.9% of students are limited English language proficient (Mass Dept. of ESE,
2013b). Among the student body at Dean Tech, 69.1% of students’ first language is not English
and 30.8% of students are limited English language proficient (Mass Dept. of ESE, 2013d).
At Holyoke High School, 74.9% of students are considered low income, 68.1% of
students qualify for free lunch, and 6.8% of students qualify for reduced lunch (Mass Dept. of
ESE, 2013b). At Dean Tech, 95.6% of students are considered low income, 91.5% of students
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qualify for free lunch, and 4.1% of students qualify for reduced lunch (Mass Dept. of ESE,
2013d). To qualify for free or reduced lunch in the state of Mass., the parent(s)/caregiver(s) must
have an annual household income before taxes that does not exceed $26,955 if two people live in
the household; $33,874 if three people live in the household; $40,793 if four people live in the
household; $47,712 if five people live in the household; $54,631 if six people live in the
household; $61,550 if seven people live in the household; and $68,469 if eight people live in the
household. For larger households, add $6,919 for each additional person in the home
(Benefits.gov, 2012). In 2009/2010, the national average of high school students who were
eligible to receive free or reduced lunch rates was 38% (Institute of Educational Sciences, 2010).
In 2012, out of 340 students who entered ninth grade at Holyoke High School in 2008,
the 4-year graduation rate was 67.9%. Among the other students who did not graduate in four
years, 7.9% were still attending school, 16.2% had dropped out, 3.2% had completed their
education but had not graduated, and 3.8% had earned a GED (Mass Dept. of ESE, 2012a). In
2012, out of 167 students who entered 9th grade at Dean Tech in 2008, the 4-year graduation rate
was 27.5%. Among the other students who did not graduate in four years, 15.6% were still
attending school, 30.5% had dropped out, 10.8% had completed their education but had not
graduated, and 3.0% had earned a GED (Mass Dept. of ESE, 2012b). The national average 4year graduation rate in public schools is 75.5% and the average in the state of Mass. is over 80%
(Institute of Educational Sciences, 2012). Students attending Holyoke High School and Dean
Tech are a racially and ethically diverse group of adolescents who come from a low
socioeconomic and education status.
ACIP recommends that HPV vaccination begin in adolescents starting at ages 11 to 12 so
that children receive the vaccine before they begin having sexual contact, yet they point out that
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both males and females ages 13 to 26, also benefit from the vaccine. Males and females between
the ages of 13 to 26 who have not had sexual contact will benefit from the vaccine and those who
already are sexually active may not have been exposed to all the oncogenic strains of HPV and
the vaccine will provide benefit to them as well (CDC, 2007; CDC, 2011c). Even though
students attending Holyoke High School and Dean Tech are older than age 12, the HPV vaccine
is beneficial to them if they have not already received the three dose series.
Needs Assessment/Organizational Analysis
Mary Fago, Adult Nurse Practitioner (ANP), clinical director of Holyoke’s SBHCs was
interviewed by the Doctorate of Nursing Practice (DNP) student researching capstone project
ideas related to HPV vaccination rates and SBHCs. Holyoke Public Schools have three SBHCs
and two of them are located at Holyoke High School and Dean Tech. It became apparent that
there was a need to educate adolescents and their parents about HPV and the HPV vaccine. The
sites have offered the HPV vaccine, but have not had time to do education with students and their
parents about the vaccine, so very few doses have been administered. At these SBHC sites there
are likely many missed opportunities for adolescents to receive the HPV vaccine (M. Fago,
personal communication, February 14, 2013).
The Director also revealed that she felt there is a lack of awareness about HPV and the
HPV vaccine amongst adolescents and their parents. A new sex education program was
implemented at the high schools three years ago, but no specific content was included about
HPV and its consequences and the HPV vaccine. The Director stated she would like to do more
education about HPV and the HPV vaccine, but has lacked the time to do so.
An assessment and analysis of the situation at Holyoke High School and Dean Tech was
performed with the Director and it was determined that an HPV education project was needed for
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both adolescents and parents. As mentioned previously, Black and Hispanic women have higher
rates of cervical cancer and women who lived in households with incomes at less than 200
percent of the poverty level or had not graduated from high school, were less like to have had a
Pap test. Black women have higher rates of vaginal and oropharyngeal cancer and Black men
have higher rates of oropharyngeal and anal cancer. Hispanic men have higher rates of penile
cancer. A large proportion of the students attending Holyoke High School and Dean Tech are
Hispanic and the majority of them live below the poverty level, which puts them at a higher risk
for HPV-associated cancers. Also mentioned previously were the low rates of HPV vaccine
series completion and that SBHCs are an opportune location to receive all three doses. Students
do not have to miss school as the vaccine is provided on site and parents need to have only
signed a consent form, but do not need to be present when the vaccines are given.
Stakeholder Support
The Director, the school nurse leader, and the head of health education for Holyoke
Public Schools approved this capstone project. Mary Fago signed the letter of agreement
(Appendix B).
Resources, Barriers, and Facilitators
The resources needed to implement this research translation project were space, supplies,
and time. Space was needed to teach students and parents about HPV and the HPV vaccine.
Supplies were needed to create educational materials that are appropriate for both adolescents
and their parents. The HPV vaccine is available in the school-based clinic. Time was needed to
create the educational materials, to teach the students do outreach to parents, and to gather and
analyze the results of the project. The DNP student managed her time to complete the listed tasks
during the spring 2013 semester.
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Teachers, parents and adolescents could have been potential barriers to the success of this
project. If teachers were not supportive of the HPV vaccine, they could have persuaded
adolescents to not get the vaccine or not create a supportive learning environment for students to
be educated about HPV and the HPV vaccine. Parents who were not supportive of the HPV
vaccine could have convinced their children that the vaccine is harmful or not necessary and they
have the ultimate say as to whether their child receives the vaccine. Adolescents who were
fearful or misinformed about the vaccine could also have persuaded their parents to not let them
receive the vaccine.
The primary facilitators of the capstone project were the DNP student and the student’s
capstone project committee. The DNP student was responsible for completing the work and the
committee was there to advise, mentor, and guide the student through all phases of the project.
Other facilitators of the capstone project were Mary Fago, clinical director of Holyoke’s SBHCs
and the health teachers at Holyoke High School and Dean Tech.
Protocol/Plan
Goals and objectives. There were two primary objectives of this capstone project. The
first goal was to increase knowledge about HPV and the HPV vaccine in students and parents of
students who attend Holyoke High School and Dean Tech. The second goal was to increase the
number of parents of adolescents who intended to vaccinate their adolescents against HPV and
also increase the number of adolescents who intended to receive the HPV vaccine.
Project design and evaluation. The research translation method that was used for this
project was an educational intervention and the Plan-Do-Study-Act (PDSA) model. PDSA
projects are used when “…data are collected to demonstrate that change by interventions resulted
in improvement” (Speroff & O’Connor, 2004, p. 21). A PDSA project was used to develop an
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intervention to educate parents and adolescents about HPV and the HPV vaccine, which will
then lead to higher intent to vaccinate adolescents against HPV.
For this project, evidence-based research had already been collected. The rationale for
this project was centered on evidence-based research that shows when the HPV vaccine is
offered in a school-based setting, vaccine rates are higher (Brabin et al., 2008; Reiter et al., 2012)
and that parents and adolescents need more education about HPV and the HPV vaccine. Based
on this research, a proposed protocol was developed to educate parents and adolescents about
HPV and the HPV vaccine and then they would be reminded of the opportunity to vaccinate their
adolescents through the SBHC (Plan).
The DNP student attended ninth grade health classes at both Holyoke High School and
Dean Tech to teach content to students about HPV and why they should receive the HPV vaccine.
The DNP student did one 50-minute class period with each section of ninth grade health class at
both schools. The presentation emphasized that the vaccine is now available for boys as well as
girls and that it is important for both sexes to receive the vaccine. The information presented to
the students was taken from the CDC website and also from an HPV curriculum developed by
Planned Parenthood for parents and adolescents (Bernstein et al., 2008) and formulated into an
interactive presentation and educational handout (Appendix C). A demographic instrument and
pre-test (Appendix D) was prepared and administered at the beginning of class. Post-tests
(Appendix E) were also prepared and administered at the end of class after the educational
intervention (Do).
The DNP student had proposed to give a presentation to parents about HPV and the HPV
vaccine and provide parents with an opportunity to ask questions and discuss their concerns
about the vaccine at the high schools or the Holyoke Boys and Girls Club parent night. A
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demographic instrument pre-test (Appendix F) and post-test (Appendix G) were prepared for a
parent presentation, but the presentation was cancelled and unable to be rescheduled. The high
schools did not have a forum for this type of presentation and the Boys and Girls Club was not
able to reschedule the presentation during the project timeframe (Do).
The questions for the pre-tests and post-tests for both the adolescents and the parents
were based on a study (permission was obtained by the DNP student) by Kennedy, Sapsis,
Stokley, Curtis, and Gust (2011), the Planned Parenthood HPV curriculum (Bernstein et al.,
2008), and the HBM. The standardized pre-test and post-test were comprised of the exact same
ten multiple-choice questions. The questions were used to measure knowledge levels about HPV
and the HPV vaccine, their perceived severity to HPV, the perceived benefits of the HPV
vaccine, the perceived barriers of the HPV vaccine, their cues to action about receiving the HPV
vaccine, and their intent to receive the HPV vaccine (Do).
The DNP student did outreach to parents to inform them about HPV and the HPV
vaccine. The student staffed a Teen Clinic table at a parent information night at Holyoke High
School for parents of incoming ninth graders. The table had information about the HPV vaccine,
the Teen Clinic, and the DNP student spoke with parents about the HPV vaccine and that the
vaccine was available through the Teen Clinic. The student also staffed a table on behalf of the
Teen Clinic at a 5K run in Holyoke and had information about HPV and the HPV vaccine for
parents and adolescents. The student had a sign that stated, “Come talk about HPV and get a
popsicle for free” to give people an incentive to visit the table. The student spoke with parents
and adolescents and gave them information and answered their questions about HPV and the
HPV vaccine (Do).
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The DNP student prepared an informational handout that was sent home with all ninth
grade students at Holyoke High School and Dean Tech. The handout was an information sheet
written by the CDC (Appendix H) with a small attachment stapled to it (Appendix I) that
reminded parents and students that the SBHC had the HPV vaccine available and was an
opportune site for students to receive the HPV vaccine. The attachment provided information on
how adolescents could schedule an appointment at the SBHC. The handout was double-sided in
both English and Spanish. Informational brochures and posters that are specifically aimed at
adolescents were also ordered and obtained about HPV and the HPV vaccine and were placed in
the SBHC (Do).
To evaluate the project outcomes, three instruments were used: the demographic
instrument (no identifying information was collected from students), the pre-test, and post-test.
All data collected during the protocol was analyzed to see if the goals of the project were
accomplished. (Study).
The first goal of increasing knowledge about HPV and the HPV vaccine in students and
their parents was only evaluted in the students by administering the pre-test and post-test before
and after the eductional intervention. Improvement in the test scores demonstrated an increase in
knowledge in the students. The second goal of increasing the number of parents of adolescents
who intended to vaccinate their adolescents against HPV and also increasing the number of
adolescents who intended to receive the HPV vaccine, was only evaluated in the adolescents.
This was measured on the adolescents’ pre-tests and post-tests. Students were asked on the pretest if they have received the HPV vaccine and if not, whether they intended to receive the HPV
vaccine. On the post-test, students were again asked if they intended to receive the HPV vaccine.
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An increase in adolescents who intended to receive the HPV vaccine demonstrated that the
project was successful.
Then all the data was reviewed and analyzed. It was determined the protocol was
successful and knowledge about HPV and the HPV vaccine increased and intent to vaccinate
rates increased. It was also determined that the fliers and consent forms could be sent home to
students in other grades at Holyoke High School and Dean Teach or at other schools that have
SBHCs to increase HPV awareness and vaccination rates at those sites as well (Act).
Costs and resources. The expenses for this project were staff time and supplies. Staff
time was needed to allow the DNP student to present in the ninth grade health classes. Time was
needed to create/gather the educational materials, to teach the students, to do outreach to the
parents, and to gather and analyze the results of the project. The location for the educational
programs for the adolescents was at school and there was no fee involved. The supplies for the
educational program and the parent outreach were approximately $300. The DNP student
covered this cost. Brochures and posters were ordered at no cost from the CDC, which the DNP
student used and reproduced on a copy machine.
IRB approval and ethical considerations. This capstone project did not require IRB
approval because this was a student program improvement project. The project involved human
subjects, but did not involve any research activities. No identifying information was collected on
the adolescents or their parents.
Implementation and timeline. The capstone project proposal was approved by the DNP
student’s capstone committee in March 2013, before the project began. Once the committee
approved the proposal, the DNP student immediately created and ordered the educational
materials needed for the educational sessions, the pre and post-tests for the students and parents
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were written, and supplies for the parent outreach were gathered. The informational handout for
parents was also prepared and copied. The educational interventions and parent outreach was
performed during May and June 2013. The data was analyzed and the final write-up of the
capstone project was completed in May and June 2013. The timeline below was the proposed
workplan for the capstone project in 2013.
Table 1. Timeline
Task
Capstone
Project
Proposal
Develop
Parent
Information
Form
Develop
Student/Parent
Educational
Information
Educational
Sessions with
Students and
Parents
Data
Collection and
Analysis
Interpretation
of Results
Complete
Capstone
Write-up

March
X

April

X

X

X

X

May

June

X

X

X

X

X

X

X

X

X
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Evaluation
Demographic Data
The adolescent sample was a convenience sample of all ninth graders who had health
class during the spring semester at Holyoke High School and Dean Tech. This comprised about
half of the entire ninth grade class at each school. The sample was 52% female and 48% male.
Twenty-one percent of the students were 14 years old, 62% were 15 years old, 16% were 16
years old, and 1% was 17 years old. Out of the sample, 63% of students identified as Hispanic,
18% as white, 12% as Hispanic, more than one race, 5% as non-Hispanic, more than one race,
and 2% as Black or African American.
Data Analysis-Pre-tests/Post-tests
The DNP student entered all data from the adolescents’ pre-tests and post-tests into an
Excel spreadsheet. Only adolescents who completed the demographic data, pre-test, and post-test
results were used in this analysis (N=164). More students (N=169) were present for the
educational intervention, but they had missing data. The mean scores from each question were
calculated and scores from the pre-tests were compared with the post-tests scores. Scores were
compared for the group as a whole and also scores of males versus females. No data was able to
be collected from the parents because the presentation for the parents was not performed and the
two outreach sessions for parents were not amenable to collecting data.
Table 2 shows all the students’ mean scores on each pre-test and post-test question. Table
3 shows the students’ mean scores on each pre-test and post-test question, but compares the
scores by sex.
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Table 2. Entire Group Scores
Question
1-If I am infected with HPV, I could
get genital warts and/or cancer.

Pre-Test Score

Post-Test Score

Agree-26%

Agree-95%

Disagree-14%

Disagree-2%

Unsure-60%

Unsure-3%

2-HPV is one of the most common
True-72%
sexually transmitted infections in the
United States.
False-28%

True-98%

3-The highest rates of new genital
HPV infections occur in young
adults between the ages of 15-24.

87%-True

True-94%

13%-False

False-6%

4-How is HPV transmitted? Select
7% Chose A & D
all the correct answers.
A. Skin-to-skin contact
95% Chose A or D
B. Contact with infected blood
C. An infected person coughs or
sneezes on another person
D. Vaginal, oral, or anal sex
5-Who should receive the HPV
1% Girls only
vaccine?
0% Boys only

6-Have you received the HPV
vaccine?
*If you answered yes to question 6,
do not answer any more questions

7-I believe I could be at risk (now or
in the future) for getting HPV.

8-There is a vaccine I could receive
to prevent myself from getting the
most serious types of HPV.

False-2%

62% Chose A & D
100% Chose A or D

1% Girls only
0% Boys only

99% Girls and Boys

99% Girls and Boys

Yes-19%

Yes-33%

No-27%

No-27%

Unsure-54%

Unsure-40%

Agree-15%

Agree-43%

Disagree-36%

Disagree-23%

Unsure-49%

Unsure-34%

Agree-65%

Agree-87%
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9-There is someone I could talk to
(parent, nurse, doctor, friend,
teacher) about my questions and
concerns about HPV and the HPV
vaccine.
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Disagree-3%

Disagree-1%

Unsure-32%

Unsure 12%

Agree-81%

Agree-92%

Disagree-3%

Disagree-2%

Unsure-16%

Unsure-6%

10-If you have not received the HPV Yes-63%
vaccine, do you intend to get the
HPV vaccine in the future?
No-4%
Unsure-33%

Yes-76%
No-4%
Unsure-20%
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Table 3. Males Versus Female Scores
Question
1-If I am infected with HPV, I
could get genital warts and/or
cancer.

2-HPV is one of the most
common sexually transmitted
infections in the United States.

3-The highest rates of new
genital HPV infections occur
in young adults between the
ages of 15-24.

4-How is HPV transmitted?
Select all the correct answers.
A. Skin-to-skin contact
B. Contact with infected
blood
C. An infected person
coughs or sneezes on
another person
D. Vaginal, oral, or anal
sex
5-Who should receive the
HPV vaccine?

Pre-Test Score
Males
Agree-28%

Females
Agree-25%

Post-Test Score
Males
Agree-94%

Females
Agree-97%

Disagree-16% Disagree-10% Disagree-3%

Disagree-1%

Unsure-56%

Unsure-2%

Males

Unsure-65%
Females

Unsure-3%
Males

Females

True-66%

True-77%

True-97%

True-98%

False-34%

False-23%

False-3%

False-2%

Males

Females

Males

Females

True-86%

True-87%

True-92%

True-95%

False-14%

False-13%

False-8%

False-5%

Males

Females

8% chose A
and D

91% chose A
or D

Males

5% chose A
and D

99% chose A
or D

Females

Males

Females

53% chose A

73% chose A

and D

and D

100% chose

100% chose

A or D

A or D

Males

Females

Girls only-2% Girls only-0% Girls only-1% Girls only-0%
Boys only-0% Boys only-0% Boys only-0% Boys only-0%

6-Have you received the HPV
vaccine?

Girls and
Boys-98%
Males

Girls and
Boys-100%
Females

Girls and
Boys-99%
Males

Girls and
Boys-100%
Females
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7-I believe I could be at risk
(now or in the future) for
getting HPV.
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Yes-18%

Yes-13%

Yes-33%

Yes-33%

No-35%

No-37%

No-27%

No-27%

Unsure-47%

Unsure-50%

Unsure-40%

Unsure-40%

Males
Agree-18%

Females
Agree-13%

Males
Agree-45%

Females
Agree-41%

Disagree-35% Disagree-37% Disagree-22% Disagree-35%
Unsure-47%
8-There is a vaccine I could
Males
receive to prevent myself from
getting the most serious types Agree-60%
of HPV.
Disagree-5%
Unsure-35%
9-There is someone I could
talk to (parent, nurse, doctor,
friend, teacher) about my
questions and concerns about
HPV and the HPV vaccine.

10-If you have not received
the HPV vaccine, do you
intend to get the HPV vaccine
in the future?

Males

Unsure-50%
Females

Unsure-33%
Males

Unsure-24%
Females

Agree-69%

Agree-83%

Agree-91%

Disagree-1%

Disagree-0%

Disagree-2%

Unsure-30%

Unsure-17%

Unsure-7%

Females

Males

Females

Agree-81%

Agree-82%

Agree-91%

Agree-93%

Disagree-5%

Disagree-1%

Disagree-2%

Disagree-2%

Unsure-14%

Unsure-17%

Unsure-7%

Unsure-5%

Males

Females

Males

Females

Yes-63%

Yes-63%

Yes-74%

Yes-78%

No-5%

No-3%

No-6%

No-2%

Unsure-32%

Unsure-34%

Unsure-20%

Unsure-20%
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Interpretation of the Findings
The data was analyzed by looking at the findings that were relative to the pre-test and
post-test question clusters that align with each construct of the HBM. The questions that had to
do with knowledge about HPV and the HPV vaccine all had an increase in scores. In the pre-test,
72% of students answered the question that HPV is one of the most common sexually
transmitted diseases in the U.S. correctly and in the post-test, 98% of students answered it
correctly. In the pre-test, 66% of males answered the question correctly and in the post-test, 97%
of males answered it correctly, versus 77% of females in the pre-test and 98% of females in the
post-test. In the pre-test, 87% of student answered the question that the highest rates of new
genital HPV infections occur in young adults between the ages of 15-24 correctly and in the
post-test, 94% answered it correctly. In the pre-test, 86% of males answered the question
correctly and in the post-test, 92% of males answered it correctly, versus 87% of females in the
pre-test and 95% of females in the post-test. In the pre-test, 7% of students identified both ways
HPV is transmitted, by skin-to-skin contact and through vaginal, oral, or anal sex correctly and in
the post-test, 62% identified both answers correctly. In the pre-test, 8% of males and 5% of
females identified both answers correctly and in the post-test, 53% of males and 73% of females
identified both answers correctly. In the pre-test, 95% of students identified one of the two ways
HPV is transmitted correctly and that increased to 100% in the post-test. In the pre-test, 91% of
males and 99% of females could identify one of the two ways, which also increased to 100% in
both groups in the post-test. In both the pre-test and post-test, 99% of students knew that both
girls and boys should receive the HPV vaccine. In the pre-test and post-test, 100% of females
answered this question. In the pre-test, 2% of males thought the HPV vaccine was for girls only
and that decreased to 1% of males in the post-test.
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In the pre-test question about the perceived severity of HPV, 26% of students agreed that
if they were infected with HPV, they could be at risk for genital warts and/or cancer. In the posttest, 95% of students agreed they could be at risk. In the pre-test, 28% of males perceived the
severity of HPV and 25% of females. In the post-test, 94% perceived the severity of HPV and
97% of females.
The pre-test asked if students had been vaccinated against HPV or if they were unsure.
Nineteen percent stated, yes they had received the vaccine, 27% stated they had not received the
vaccine, and 54% were unsure. This number should have remained the same in the post-test
because no one received the vaccine while in health class, but the numbers changed. In the posttest, 33% of students reported they had received the HPV vaccine, 27% stated they had not, and
40% stated they were unsure. These response rates were the same for males and females. In the
pre-test, 18% of males stated they had received the HPV vaccine, 35%, stated they had not, and
47% were unsure. These numbers changed in the post-test to 33% of males stating they had
received the HPV vaccine, 27% stating they had not, and 40% were unsure. In the pre-test, 13%
of females stated they had received the HPV vaccine, 37%, stated they had not, and 50% were
unsure. These numbers changed in the post-test to 33% of females stating they had received the
HPV vaccine, 27% stating they had not, and 40% were unsure.
The students who stated they had not received the HPV vaccine or were unsure if they
had received it were sorted by sex and race/ethnicity. Among the 53 males, 59% were Hispanic,
19% were white, 15% were Hispanic, more than one race, 6% were non-Hispanic, more than one
race, and 1% were Black or African American. In the 56 females who reported they had not
received the HPV vaccine or were unsure, 70% were Hispanic, 14% were white, 8% were
Hispanic, more than once race, 4% were non-Hispanic, more than once race, and 4% were Black
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or African American. Also out of the 109 students who stated they had not received the HPV
vaccine or were unsure, 21% of them were 14 years old, 62% were 15 years old, 16% were 16
years old, and 1% was 17 years old.
If the students stated they had received the HPV vaccine, they did not answer any more
questions. If students stated they had not or were unsure if they had received they HPV vaccine,
they completed four more questions. A question about whether students felt they were at risk
now or in the future for getting HPV had responses on the pre-test that showed 15% agreed with
this statement, 36% disagreed, and 49% were unsure. In the post-test, 43% of students agreed
they could be at risk now or in the future for HPV, 23% disagreed and, 34% were still unsure. In
the pre-test, 18% of males and 13% of females felt they could be at risk for HPV, 35% of males
and 37% of females felt they were not at risk for HPV, and 47% of males and 50% of females
were unsure. In the post-test, 45% of males and 41% of females felt they could be at risk for
HPV, 22% of males and 35% of females felt they were not, and 33% of males and 24% of
females remained unsure if they were at risk now or in the future of getting HPV.
The next question asked if students thought there was a vaccine that could prevent them
from getting the most serious types of HPV, which demonstrated the perceived benefits of the
HPV vaccine. In the pre-test, 65% of students agreed with this statement, 3% disagreed, and 32%
were unsure. In the post-test, 87% of students agreed with this statement, 1% disagreed, and 12%
remained unsure. In the pre-test, 60% of males and 69% of females agreed there was a vaccine
that could prevent them from getting HPV, 5% of males and 1% of females disagreed, and 35%
of males and 30% of females were unsure. In the post-test, 83% of males and 91% of females
agreed, 0% of males and 2% of females disagreed, and 17% of males and 7% of females
remained unsure.
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In the pre-test, 81% of students agreed, 3% disagreed, and 16% were unsure if there was
someone they could talk to about their questions and concerns about HPV and the HPV vaccine.
This assessed whether students felt there were perceived barriers to getting the HPV vaccine. In
the post-test, 92% of students agreed there was someone they could talk to, 2% disagreed, and
6% remained unsure. In the pre-test, 81% of males and 82% of females agreed there was
someone they could talk to, 5% of males and 1% of females disagreed, and 14% of males and
17% of females were unsure. In the post-test, 91% of males and 93% of females agreed there
was someone they could talk to about HPV. Two percent of males and 2% of females disagreed
with this and 7% of males and 5% of females remained unsure if there was someone they could
talk to about HPV.
The last question asked the students who had answered that they had not received the
HPV vaccine, whether they intended to get the HPV vaccine in the future. This assessed the
students’ cues to actions. In the pre-test, 63% of students stated they intended to receive the HPV
vaccine, 4% stated they did not intend to received the HPV vaccine, and 33% were unsure. In the
post-test, 76% of students stated they intended to receive the HPV vaccine, 4% stated they did
not intend to receive it, and 20% remained unsure. In the pre-test, 63% of both males and
females stated they intended to receive the HPV vaccine, 5% of males and 3 of females stated
they did not intend to receive the HPV vaccine, and 32% of males and 34% of females were
unsure. In the post-test, 74% of males and 78% of females stated they intended to receive the
HPV vaccine, 6% of males and 2% of females stated they did not intend to receive the HPV
vaccine, and 20% of both males and females remained unsure about whether they intended to
receive the HPV vaccine.
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There was also feedback that was not purposefully gathered during this capstone project,
but is important to be presented here. The DNP student reported that the ninth grade students
were very engaged during the class periods. Students asked a plethora of questions about HPV
and the HPV vaccine. One student stated “Thank you for taking the time to inform us about this.”
Another student stated, “Why hasn’t anyone else told us about HPV, this is important!” A group
of three girls after the presentation stated they were all going to the Teen Clinic after school to
pick up permission slips to take home for their parents to sign. At least five students stated they
were taking the HPV handout they received in class home to their parents to talk about with them.
When discussing possible side effects of the HPV vaccine, three students in different periods all
raised their hands and commented that they had recently received the vaccine. Two reported
having no side effects and one stated, “It hurt a little, but I am fine.” One parent at an outreach
session stated, “My son can receive this vaccine? I didn’t know that. I will make him an
appointment right away.”
Discussion
The first goal of increasing knowledge about HPV and the HPV vaccine in students and
their parents was partially met. Results from the educational intervention with the students
showed an increase in knowledge about HPV and the HPV vaccine. There was a 26% overall
increase in scores on the question about HPV being one of the most common sexually
transmitted diseases in the U.S. There was a 7% overall increase in scores on the question about
the highest rates of new genital HPV infections occuring in young adults ages 15-24. There was
also a 55% overall increase in the scores on the question about identifying both ways HPV is
transmitted. There may have been an increase in knowledge amongst parents to whom the DNP
student spoke to at the outreach events, but there was no way to measure that outcome.
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The second goal of increasing the number of parents of adolescents who intended to
vaccinate their adolescents against HPV and also increase the number of adolescents who
intended to receive the HPV vaccine was also partially met. Results from the educational
intervention with the students showed an increase in the overall number of adolescents who
intend to get the HPV vaccine in the future. There was a 13% increase in intent in the
adolescents from the pre-test to the post-test. There may have been an increase in parents to
whom the DNP student spoke to at the outreach events who intended to vaccinate their
adolescents against HPV, but again there was no way to measure that outcome.
The results demonstrated that students may be ready to act on a health decision as in the
contstructs of the HBM. Students learned about their perceived susceptibility/severity of HPV
with a 69% overall increase in students who stated that if they were infected with HPV, they
could get genital warts and/or cancer. There was a 22% overall increase in students who stated
there is a vaccine they could receive to prevent themselves from getting the most serious types of
HPV, the perceived benefits. Students had 11% overall increase in those that reported there was
someone they could talk to about their questions about HPV and the HPV vaccine, the perceived
barriers. As mentioned above, there was a 13% overall increase in students who stated they
intended to receive the HPV vaccine, which is their cue to action. The last step of the HBM is
self-efficacy, which could not be captured in this project as there was no way to measure how
many students actually received the HPV vaccine, but students and their parents now have tools
to assist them in making an informed decision.
One unexpected finding in the results was the number of students who reported they had
already received the HPV vaccine.. As mentioned above, this number should have remained the
same in the post-test because no one received the vaccine while in health class, but the numbers
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increased in those that reported they had already received the HPV vaccine on the post-test. The
students were not given any information about HPV before the pre-test, so the DNP student
surmises that the students did not know the vaccine by name, but when they heard it referred to
as Gardasil or as the vaccine against cancer, many students realized they had in fact already
received the vaccine. The post-test results also showed that the males and females reported the
exact same vaccination rates, 33% stated they had received the HPV vaccine, 27% stated they
had not, and 40% were unsure. These results do not match national data, which shows vaccine
rates amongst males being much lower than amongst females. However, the reported vaccine
rates were low overall, which does match the national data. As mentioned previously, the rate of
HPV vaccination completion in females, ages 13-17 in Massachusetts is 48.5%, which is higher
than the 33% of females in this group who reported they had been vaccinated.
The results from the students and the qualitative data from the parent outreach sessions
match the findings of the literature review. Adolescents and their parents are not aware of HPV
or its consequences and the HPV vaccine. This capstone project also demonstrated that schools
with SBHCs are ideal locations to educate adolescents about HPV and the HPV vaccine.
Students were excited to hear that the HPV vaccine was available at the Teen Clinic.
As mentioned previously, rates of cervical cancer are disproportionately higher in
Hispanic and Black women. In this sample, out of the females who reported they had not been
vaccinated against HPV or were unsure if they had been vaccinated, 70% were Hispanic, 8%
Hispanic, more than once race, and 4% Black or African American. Also HPV-associated penile
cancer is highest in Hispanic men. In this sample, out of the males who reported they had not
been vaccinated against HPV or were unsure if they had been vaccinated, 59% were Hispanic
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and 15% were Hispanic, more than one race. This demonstrates a need for adolescents,
especially Hispanics and Blacks, to get vaccinated against HPV.
The study by Read et al. (2010) reported that 48.9% of females, ages 13-19, reported
being sexually active by 14.9 years of age and over half of them had had more than one sexual
partner. In this sample, amongst the adolescents who stated they had not received the HPV
vaccine or were unsure if they had, 21% of them were 14 years of age, 62% 15 years of age, 16%
16 years of age, and 1% 17 years of age. Though the students were not asked if they were
sexually active, based on data from the Read et al. study, one can assume that some of these
students are already sexually active and a large proportion of them are not vaccinated against
HPV.
Limitations/Recommendations
The findings of this capstone project should be interpreted in light of several limitations.
First, not being able to secure a formal parent group to collect quantitative data from parents was
a process failure, whereby part of the intended intervention was not able to be implemented (Issel,
2009). Another barrier to conducting the parent group was the timeframe the DNP student had to
implement this invention in order to comply with the academic requirements of the semester. If
the DNP student had more time, perhaps the parent group could have been implemented. An
additional limitation of this project was it relied on self-report. Self-report of data from
adolescents may not be reliable (Burns & Grove, 2009). Another limitation of this project was
the group being a convenience sample, which is a threat to the validity of the data (Burns &
Grove, 2009).
Future projects within this population should focus on how to engage parents in the HPV
vaccine decision-making for their children, but as evidenced by this project, it is difficult to find

INCREASING HPV VACCINATION RATES

44

a setting in which to conduct this type of intervention. Projects should also be implemented over
a longer period of time and nurses should find a way to access health records of students to
measure whether the rates of HPV vaccination actually increased after an educational
intervention. Also future projects should have a comparison group, where one sample of students
and parents receive an educational intervention versus a sample who do not get the intervention
and HPV vaccination rates should be measured and compared.
Conclusion/Future Implications
The results of this capstone project did show an increase in knowledge about HPV and
the HPV vaccine and an increase in intent to vaccinate against HPV in adolescents. Schools,
particularly those with SBHCs or vaccine clinics, are an opportune venue to teach adolescents
about HPV and the HPV vaccine. The DNP student is hopeful that the health teachers will
continue to teach HPV content in their health classes, as they were provided with the information
to do so, and it could be done in the time of one class period. The student is also hopeful that the
SBHCs in Holyoke High School and Dean Tech will continue to do outreach to adolescents and
parents about the HPV vaccine, and as a result, HPV vaccination rates will increase over time.
This project is evidence that there is still a need for increased education targeting parents
and adolescents about HPV and the HPV vaccine. Public health nurses and nurses who work in
SBHCs are in an important position to do further research and evaluation about how to best reach
this population and continue HPV vaccination efforts. Future projects and research about HPV
and the HPV vaccine can lead to a more informed U.S. population, which should result in
increased HPV vaccination rates and therefore, in fewer HPV-related cancer cases.
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Appendix C
HPV Fact Sheet
What is HPV?
HPV stands for human papillomavirus. HPV is a virus that is passed from one person to
another by skin-to-skin sexual contact including vaginal, oral, and anal sex. HPV can cause
genital warts or cell changes that can lead to cancer.
More About HPV
HPV is one of the most common sexually transmitted infections in the U.S. Almost all
sexually active people will get HPV at some time in their lives, but most will never know it.
74% of new HPV infections are in young people ages 15-24. Most of the time, the body
naturally fights off HPV, but not always and it can lead to health problems.
Does HPV Cause Cancer?
Yes. HPV causes cancer in the cervix, vulva, and vagina in women and the penis in men. It
causes cancer in the mouth/throat and anus in both men and women. Every year, HPV
causes cancer in 18,000 women and 7,000 men in the U.S.
How Do I Know if I Have HPV?
Unless you have genital warts, most people do not have symptoms from HPV. There is no
routine test for HPV. For women, screening for cervical cancer is done with a Pap smear.
Is There a Vaccine Available Against HPV?
YES! The most common vaccine is Gardasil, which protects people from the 4 most
common strains of HPV that cause genital warts and cancer. The vaccine is 3 shots, given
over a period of 6 months.
Who Should Get the HPV Vaccine? Where Can I Get the Vaccine?
All boys and girls ages 9 to 26 should get the HPV vaccine.
You must have your parent/guardian’s permission to get the vaccine. It is available at the
Teen Clinic or at your doctor’s office.
Is the HPV Vaccine Safe?
YES! 46 million doses have been given around the world and
there have been no serious concerns. Some people report mild
side effects like pain in their arm, fever, dizziness, and nausea.
How Can I Protect Myself Against HPV?
Get the HPV vaccine.
Practice abstinence.
Use condoms every time you have sex.
Limit the amount of sexual partners you have.
* Info adapted from CDC.gov
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Appendix D
Participant #_____
Demographic Information
Circle the best answer or fill in the blank for all of the following questions.
Example:
The current President of the United States is Barack Obama.
True

or

False

1. I am:
Female

Male

Other (Transgender)

2. How old are you?
__________

3. I am:
Hispanic
White
African American/Black
Asian
Native American
Native Hawaiian/Pacific Islander
Multi-Race, Non-Hispanic
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Participant #_____

Pretest
Circle the best answer or fill in the blank for all of the following questions.
Example: The current President of the United States is Barack Obama.
True

or

False

1. If I am infected with human papillomavirus (HPV), I could get genital warts and/or cancer.
Agree

Disagree

Unsure

2. HPV is one of the most common sexually transmitted infections in the United States.
True

or

False

3. The highest rates of new genital HPV infections occur in young adults between the ages of 15-24.
True

or

False

4. How is HPV transmitted? Select all the correct answers.
A. Skin-to-skin contact
B. Contact with infected blood
C. An infected person coughs or sneezes on another person
D. Vaginal, anal, or oral sex
5. Who should receive the HPV vaccine?
Girls only

Boys only

Both girls and boys

6. Have you received the HPV vaccine?
Yes

No

Unsure

If you answered yes to question # 6, do not answer any more questions
7. I believe I could be at risk (now or in the future) for getting HPV.
Agree

Disagree

Unsure

8. There is a vaccine I could receive to prevent myself from getting the most serious types of HPV?
Agree

Disagree

Unsure

9. There is someone I could talk to (parent, nurse, doctor, friend, teacher) about my questions and
concerns about HPV and the HPV vaccine.
Agree

Disagree

Unsure
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10. If you have not received the HPV vaccine, do you intend to get the HPV vaccine in the future?
Yes

No

Unsure
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Appendix E
Postest

Participant #_____

Circle the best answer or fill in the blank for all of the following questions.
Example: The current President of the United States is Barack Obama.
True

or

False

1. If I am infected with human papillomavirus (HPV), I could get genital warts and/or cancer.
Agree

Disagree

Unsure

2. HPV is one of the most common sexually transmitted infections in the United States.
True

or

False

3. The highest rates of new genital HPV infections occur in young adults between the ages of 15-24.
True

or

False

4. How is HPV transmitted? Select all the correct answers.
A. Skin-to-skin contact
B. Contact with infected blood
C. An infected person coughs or sneezes on another person
D. Vaginal, anal, or oral sex
5. Who should receive the HPV vaccine?
Girls only

Boys only

Both girls and boys

6. Have you received the HPV vaccine?
Yes

No

Unsure

If you answered yes to question # 6, do not answer any more questions
7. I believe I could be at risk (now or in the future) for getting HPV.
Agree

Disagree

Unsure

8. There is a vaccine I could receive to prevent myself from getting the most serious types of HPV?
Agree

Disagree

Unsure

9. There is someone I could talk to (parent, nurse, doctor, friend, teacher) about my questions and
concerns about HPV and the HPV vaccine.
Agree

Disagree

Unsure
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10. If you have not received the HPV vaccine, do you intend to get the HPV vaccine in the future?
Yes

No

Unsure
Thank you for your time and participation.
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Appendix F
Participant #_____
Demographic Information
Circle the best answer or fill in the blank for all of the following questions.
Example:
The current President of the United States is Barack Obama.
True

or

False

1. I am the parent/guardian of a child entering the 9th grade next year.
Yes

or

No

If you answered No, you do not need to answer any more questions.
2. My child is:
Male

Female

Other (Transgender)

3. The current age of my child is:
________________
4. I am:
Male

Female

Other (Transgender)

5. I am:
Hispanic
White
African American/Black
Asian
Native American
Native Hawaiian/Pacific Islander
Multi-Race, Non-Hispanic
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Participant #_____

Circle the best answer or fill in the blank for all of the following questions.
Example: The current President of the United States is Barack Obama.
True

or

False

1. How is human papilloma virus (HPV) transmitted? Select all the correct answers.
A. Skin-to-skin contact
B. Contact with infected blood
C. An infected person coughs or sneezes on another person
D. Vaginal, anal, or oral sex
2. Who should receive the HPV vaccine?
Girls only

Boys only

Both girls and boys

3. Has your adolescent child received the HPV vaccine?
Yes
No
Unsure
If you answered yes to question #3, do not answer any more questions
4. I believe my adolescent child could be at risk (now or in the future) for getting HPV.
Agree
Disagree
Unsure
5. My adolescent child could get genital warts and/or cancer someday if he/she does not receive the
HPV vaccine.
Agree

Disagree

Unsure

6. There is a vaccine my adolescent child could receive to prevent him/her from getting the most
serious types of HPV.
Agree

Disagree

Unsure

7. The HPV vaccine is safe for my adolescent child.
Agree

Disagree

Unsure

8. My adolescent child should receive the HPV vaccine if his/her healthcare provider recommends it.
Agree

Disagree

Unsure

9. I have access to all the information I need to make a good decision about having my adolescent
child receiving the HPV vaccine.
Yes

No

Unsure
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10. If your adolescent child has not received the HPV vaccine, do you intend to have him/her get the
HPV vaccine in the future?
Yes

No

Unsure
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Appendix G
Posttest

Participant #_____

Circle the best answer or fill in the blank for all of the following questions.
Example: The current President of the United States is Barack Obama.
True

or

False

1. How is human papilloma virus (HPV) transmitted? Select all the correct answers.
A. Skin-to-skin contact
B. Contact with infected blood
C. An infected person coughs or sneezes on another person
D. Vaginal, anal, or oral sex
2. Who should receive the HPV vaccine?
Girls only

Boys only

Both girls and boys

3. Has your adolescent child received the HPV vaccine?
Yes
No
Unsure
If you answered yes to question #3, do not answer any more questions
4. I believe my adolescent child could be at risk (now or in the future) for getting HPV
Agree
Disagree
Unsure
5. My adolescent child could get genital warts and/or cancer someday if he/she does not receive the
HPV vaccine.
Agree

Disagree

Unsure

6. There is a vaccine my adolescent child could receive to prevent him/her from getting the most
serious types of HPV.
Agree

Disagree

Unsure

7. The HPV vaccine is safe for my adolescent child.
Agree

Disagree

Unsure

8. My adolescent child should receive the HPV vaccine if his/her healthcare provider recommends it.
Agree

Disagree

Unsure

9. I have access to all the information I need to make a good decision about having my adolescent
child receiving the HPV vaccine.
Yes

No

Unsure
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10. If your adolescent child has not received the HPV vaccine, do you intend to have him/her get the
HPV vaccine in the future?
Yes

No

Unsure
Thank you for your time and participation.
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Appendix I

ATTENTION PARENTS!
The HPV vaccine is available at the Teen Clinic at Dean Tech or is available at your
pediatrician’s office.
If you would like to schedule an appointment for your adolescent to receive the HPV
vaccine at the Teen Clinic, please have your son or daughter come in to the Teen Clinic and
pick up a permission slip.

¡ATENCION PADRES!
La vacuna contra el VPH está disponible en la Clínica de Adolescentes en Holyoke High
School y también está disponible en el consultorio de su pediatra.
Si usted desea hacer una cita para su hijo/a para recibir la vacuna contra el VPH en la
Clínica de Adolescentes, por favor dígale a su hijo/a que se presenten a la Clínica de
Adolescentes para recoger una hoja de permiso.

